Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023925% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002007% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 18.43 |
| Open | 18.8 |
| 1-Year Change | 7.49% |
| Day's Range | 18.8 - 19.18 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 18.43 | -0.01 | -0.05% | 18.44 | 18.67 | 18.08 |
| Nov 20, 2024 | 18.41 | 0.07 | 0.38% | 18.34 | 18.48 | 18.26 |
| Nov 19, 2024 | 18.40 | 0.20 | 1.10% | 18.20 | 18.42 | 18.15 |
| Nov 18, 2024 | 18.11 | 0.02 | 0.11% | 18.09 | 18.33 | 17.88 |
| Nov 15, 2024 | 18.04 | 0.17 | 0.95% | 17.87 | 18.04 | 17.52 |
| Nov 14, 2024 | 17.93 | -0.04 | -0.22% | 17.97 | 18.08 | 17.81 |
| Nov 13, 2024 | 18.13 | -0.16 | -0.87% | 18.29 | 18.31 | 17.81 |
| Nov 12, 2024 | 18.23 | 0.03 | 0.16% | 18.20 | 18.33 | 18.01 |
| Nov 11, 2024 | 18.34 | 0.00 | 0.00% | 18.34 | 18.74 | 18.17 |
| Nov 8, 2024 | 18.24 | 0.21 | 1.16% | 18.03 | 18.40 | 17.90 |
| Nov 7, 2024 | 17.90 | 0.26 | 1.47% | 17.64 | 17.99 | 17.48 |
| Nov 6, 2024 | 17.75 | -0.60 | -3.27% | 18.35 | 18.54 | 17.44 |
| Nov 5, 2024 | 18.26 | -0.01 | -0.05% | 18.27 | 18.58 | 17.88 |
| Nov 4, 2024 | 18.38 | -0.13 | -0.70% | 18.51 | 18.80 | 18.38 |
| Nov 1, 2024 | 18.45 | 0.14 | 0.76% | 18.31 | 18.85 | 18.03 |
| Oct 31, 2024 | 18.48 | -0.31 | -1.65% | 18.79 | 18.95 | 18.32 |
| Oct 30, 2024 | 18.98 | -0.03 | -0.16% | 19.01 | 19.30 | 18.67 |
| Oct 29, 2024 | 19.21 | -0.01 | -0.05% | 19.22 | 19.28 | 18.79 |
| Oct 28, 2024 | 19.01 | -0.34 | -1.76% | 19.35 | 19.49 | 19.01 |
| Oct 25, 2024 | 19.28 | -0.11 | -0.57% | 19.39 | 19.45 | 19.00 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
| Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com